Table 2.
Clinical and laboratory characteristics within peripheral artery disease group at baseline regarding the MACE incidence during follow-up
| MACE subgroup (n=52) | Non-MACE subgroup (n=116) | P value | |
|---|---|---|---|
| Age (y) | 79 ± 13 | 74 ± 10 | 0.319 |
| Males, n (%) | 42 (80.8) | 99 (85.3) | 0.902 |
| Smoking, n (%) | 27 (51.9) | 16 (13.8) | < 0.001 |
| Hypertension, n (%) | 42 (80.8) | 83 (71.6) | 0.248 |
| Dyslipidemia, n (%) | 50 (96.1) | 112 (96.6) | 0.991 |
| Statins, n (%) | 49 (94.2) | 111 (95.7) | 0.887 |
| ABI | 0.46 (0.08) | 0.49 (0.09) | 0.821 |
| Diabetes, n (%) | 22 (42.3) | 46 (39.7) | 0.947 |
| BMI (kg/m2) | 28.22 ± 3.35 | 27.87 ± 3.11 | 0.878 |
| SBP (mmHg) | 141 ± 23 | 138 ± 22 | 0.906 |
| DBP (mmHg) | 85 ± 8 | 85 ± 9 | 0.998 |
| TChol (mg/dl) | 196 ± 57 | 177 ± 40 | 0.255 |
| HDL-C (mg/dl) | 39 ± 7 | 42 ± 10 | 0.623 |
| LDL-C (mg/dl) | 130 ± 43 | 112 ± 22 | 0.054 |
| TG (mg/dl) | 136 ± 64 | 115 ± 48 | 0.136 |
| FPG (mg/dl) | 151 ± 40 | 142 ± 33 | 0.888 |
| HbA1c (%)a | 7.5 ± 1.5 | 7.2 ± 1.3 | 0.659 |
| WBC (cells/µL) | 12,110 ± 3356 | 10,479±2777 | 0.384 |
| hsCRP (mg/L) | 10.56 ± 2.92 | 6.33±1.85 | < 0.001 |
| RBP-4 (mg/L) | 59.97 ± 21.27 | 35.87 ± 15.22 | < 0.001 |
| Adiponectin (mg/L) | 7.22 ± 2.1 | 7.67 ± 2.88 | 0.758 |
Data are expressed as means ± SD. n, number of patients; BMI, body-mass index; SBP, systolic blood pressure, DBP, diastolic blood pressure; TChol, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; WBC, white blood cells; hsCRP, high-sensitivity C-Reactive Protein
aHbA1c was measured only in diabetic patients